Kriya is a fully integrated gene therapy company on a mission to revolutionize how gene therapies are designed, developed, and manufactured- with a goal of improving speed to market and reducing cost. The company leverages its proprietary computational engine, in-house manufacturing infrastructure, and integrated design platform to engineer products with the potential to transform the treatment of a broad range of diseases. Kriya's team includes scientific pioneers with decades of experience in product development, complex manufacturing, and computational engineering.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/17/22 | $270,000,000 | Series C |
Bluebird Ventures CAM Capital Dexcel Pharma Foresite Capital JDRF T1D Fund Lightswitch Capital Narya Patient Square Capital  QVT Financial Transhuman Capital | undisclosed |
